venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
venclyxto (▼) 10 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 10 mg/1 tableta - 1 filmom obložena tableta sadrži: 10 mg venetoklaksa
venclyxto (▼) 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg venetoklaksa
venclyxto (▼) 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg venetoklaksa
venclyxto (▼) 50 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg venetoklaksa
venclyxto 10 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 10 mg/1 tableta - 1 filmom obložena tableta sadrži: 10 mg venetoklaksa
venclyxto 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg venetoklaksa
venclyxto 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg venetoklaksa
venclyxto 50 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg venetoklaksa